Tony Cates joins Cycle Group Holdings Board of Directors Tony Cates joins Cycle Group Holdings Board of Directors News, Nityr Tony Cates joins Cycle Group Holdings Board of Directors By Holly Archer|2021-10-06T10:39:32+01:00October 6th, 2021|News, Nityr| Read More
Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE) Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE) News, Nityr Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE) By Holly Archer|2021-09-28T11:36:58+01:00September 28th, 2021|News, Nityr| Read More
Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients News, Nityr Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients By Holly Archer|2021-09-14T16:56:52+01:00September 10th, 2021|News, Nityr| Read More
Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer Corporate, News Cycle Pharmaceuticals appoints Denise Moody as Chief Operating Officer By Kierah Bircham|2021-06-28T11:44:17+01:00June 28th, 2021|Corporate, News| Read More
Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer Corporate, News Cycle Pharmaceuticals appoints Steve McCue as Chief Financial Officer By Holly Archer|2021-05-25T17:41:24+01:00May 25th, 2021|Corporate, News| Read More
Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors News, Nityr Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors By Holly Archer|2021-05-17T18:52:30+01:00April 29th, 2021|News, Nityr| Read More
NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand News, Nityr NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand By Holly Archer|2021-05-17T18:52:30+01:00March 15th, 2021|News, Nityr| Read More
